The development of boron compounds for the treatment of squamous cell carcinoma of the head and neck (SCCHN) by Boron Neutron Capture Therapy (BNCT) requires the synthesis and evaluation of non-toxic agents which selectively target these malignant cells in contrast with adjacent normal tissue and are retained intracellularly. Cell membrane receptors mediating endocytotic transport of folic acid into cells are expressed in elevated levels in a variety of human tumors. The affinity of folic acid for its cell membrane receptors and its ability to be endocytosed remains essentially unaltered when a macromolecule is covalently linked to its gamma-carboxylate function. It has been shown that large numbers of conjugates of folic acid with therapeutic agents are internalized into tumor cells that overexpress the folate receptors by receptor-mediated endocytosis and are retained intracellularly. Therefore, folic acid may be an excellent carrier for the selective delivery of boron species to SCCHN.
The specific aims of this proposal are: To develop the chemical methodology to design and synthesize suitable folic acid derivatives possessing 1 to 9 carborane and polyhedral borane clusters with or without a DNA-targeting entity. To prepare folic acid conjugates with boronated starburst dendrimers using polyethylene glycol spacers as binding elements. To synthesize and incorporate boronated polyamines into a liposomal formulation using folic acid-PEG-liposomes. To determine the in vitro uptake, persistence and subcellular distribution of boronated folic acid derivatives and liposomal formulations of boronated polyamines in human squamous cell carcinoma. To study the in vivo pharmacokinetics and tumor-localizing properties in tumor bearing rodents of those boronated folate derivatives and liposomal formulations of polyamines that show high in vitro cellular uptake and persistence. To evaluate the therapeutic efficacy for BNCT of those folic acid conjugates having favorable in vivo tumor-localizing properties.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA079758-01A1
Application #
2908485
Study Section
Medicinal Chemistry Study Section (MCHA)
Program Officer
Stone, Helen B
Project Start
1999-09-01
Project End
2002-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Wu, Gong; Barth, Rolf F; Yang, Weilian et al. (2006) Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anticancer Agents Med Chem 6:167-84
Pan, Xing Q; Lee, Robert J (2005) In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res 25:343-6
Stevens, Phillip J; Sekido, Masaru; Lee, Robert J (2004) Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation. Anticancer Res 24:161-5
Stevens, Phillip J; Sekido, Masaru; Lee, Robert J (2004) A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 21:2153-7
Chiu, Shih-Jiuan; Ueno, Naoto T; Lee, Robert J (2004) Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 97:357-69
Zhao, Xiaobin B; Lee, Robert J (2004) Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 56:1193-204
Shukla, Supriya; Wu, Gong; Chatterjee, Madhumita et al. (2003) Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem 14:158-67
Stevens, Phillip J; Lee, Robert J (2003) A folate receptor-targeted emulsion formulation for paclitaxel. Anticancer Res 23:4927-31
Sudimack, Jennifer J; Guo, Wenjin; Tjarks, Werner et al. (2002) A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta 1564:31-7
Ni, Sandy; Stephenson, Stacy M; Lee, Robert J (2002) Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 22:2131-5

Showing the most recent 10 out of 16 publications